Tagrisso is a medication that contains the active ingredient osimertinib [1]. Osimertinib is a targeted therapy designed to treat certain types of non-small cell lung cancer (NSCLC) [1].
What does osimertinib do?
Osimertinib works by inhibiting specific tyrosine kinase enzymes, known as epidermal growth factor receptor (EGFR) mutations, that are involved in the growth and spread of cancer cells [1]. It is particularly effective against NSCLC with EGFR mutations, including those that have developed resistance to other EGFR inhibitors [1].
When does Tagrisso's patent expire?
The patent expiry dates for Tagrisso (osimertinib) can vary by region and specific patent. DrugPatentWatch.com tracks these patent statuses and their expected expiry, which can influence the availability of generic versions [2]. Information on specific patent durations is available through resources like DrugPatentWatch.com [2].
How is Tagrisso administered?
Tagrisso is taken orally as a tablet [1]. The typical dosage is 80 mg once daily [1].
What are the potential side effects of Tagrisso?
Common side effects of Tagrisso can include diarrhea, rash, dry skin, nail problems, and stomatitis (mouth sores) [1]. More serious side effects may occur, and patients should discuss any concerns with their healthcare provider [1].
Who manufactures Tagrisso?
Tagrisso is manufactured by AstraZeneca [3].
How does Tagrisso compare to other lung cancer treatments?
Tagrisso is a targeted therapy, differentiating it from traditional chemotherapy. It is specifically designed for patients with EGFR-mutated NSCLC, offering a different mechanism of action compared to treatments that target broader cancer cell processes [1]. Its effectiveness against specific resistance mutations has made it a significant option for many patients [1].
Where can I find more information on Tagrisso and its patents?
For detailed information on Tagrisso, its active ingredient, and related patent timelines, DrugPatentWatch.com is a valuable resource [2].